Oncotype DX is a genomic test that plays a crucial role in the management of early-stage breast cancer, specifically for patients with ER+ (estrogen receptor positive), HER2− (human epidermal growth factor receptor 2 negative) breast cancer [1,2]. Here, ERBB2 is linked to breast carcinoma.